Dozens of testosterone lawsuits currently pending in courts around the country allege that the serious cardiovascular risks associated with low testosterone therapy do not outweigh their benefits.
New York, New York (PRWEB) July 29, 2014
As testosterone treatment lawsuits (http://www.injurybeacon.com/testosterone-androgel/lawsuit/) continue to mount in U.S. courts, Bernstein Liebhard LLP notes that a new study is questioning the effectiveness of these medications in men with Type 2 diabetes. The research, which was published online by The Journal of Clinical Endocrinology & Metabolism on June 30th, involved 88 men who suffered from Type 2 diabetes, all of whom had mild to moderate aging male symptoms and erectile dysfunction. Roughly half of the study subjects were treated with a testosterone injection for 40 weeks, while the remainder received a placebo. Self-administered questionnaires were used at 0, 18 and 40 weeks to measure general health and sexual symptoms.*
During the study, no substantial improvements were seen in the men undergoing low testosterone treatment compared to those who received a placebo. The authors of the article concluded that their findings do not support the use of testosterone therapy to improve general health or sexual symptoms in men who suffer from Type 2 diabetes.
“Dozens of testosterone lawsuits currently pending in courts around the country allege that the serious cardiovascular risks associated with low testosterone therapy do not outweigh their benefits. This study would seem to substantiate those claims for this particular patient population,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating testosterone lawsuits on behalf of men who were allegedly suffered heart attacks, strokes, blood clots and other serious cardiovascular problems due to their use of low testosterone therapies.
The safety and effectiveness of testosterone replacement therapy has been under scrutiny since this past January, when the U.S. Food & Drug Administration (FDA) announced it was investigating the cardiovascular side effects associates with this class of medications. The review was prompted by two studies which indicated that older men, as well as those with pre-existing heart disease, were more likely to suffer heart attacks, strokes or death if they were using testosterone medications.
According to a notice posted on the FDA’s website, the agency will convene a joint meeting of the Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on September 17, 2014, at which time the members will be asked to make recommendations pertaining to the cardiovascular side effects associated with the medications. The Committees will also address what factors should be considered when deciding whether men need to use low testosterone therapy.*
Since the FDA announced its testosterone safety review, court documents indicate that more than 150 testosterone treatment lawsuits have been filed in U.S. courts. The majority of these claims are pending in the U.S. District Court, Northern District of Illinois, where all federally-filed testosterone lawsuits have been consolidated for coordinated pretrial proceedings. Among other things, plaintiffs in these cases allege that the manufacturers of low testosterone therapies failed to provide doctors and patients with adequate warnings regarding their serious cardiovascular side effects. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
Men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism, or other serious cardiovascular problems due to low testosterone therapy may be entitled to file their own testosterone lawsuit. To learn more, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
*press.endocrine.org/doi/abs/10.1210/jc.2014-1872, JECM, June 30, 2014
**fda.gov/AdvisoryCommittees/Calendar/ucm404905.htm, FDA, July 17, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com